Silexion Therapeutics presents promising data on SIL-204 siRNA for KRAS-driven cancers

From GlobeNewswire: 2025-01-13 07:50:00

Silexion Therapeutics Corp. will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2025. The abstract will be available online on January 21, 2025, and the poster will be on Silexion Therapeutics’ website. The presentation, titled SIL-204 siRNA, focuses on treating localized and systemic cancer with specific mutations. Silexion Therapeutics is a biotech company developing RNA interference therapies for KRAS-driven cancers, with promising results in non-resectable pancreatic cancer. The company is committed to innovating oncology treatments and improving outcomes for difficult-to-treat cancers.



Read more at GlobeNewswire: Silexion Therapeutics to Present SIL-204 Data in